PTAB Upholds AstraZeneca Diabetes Meds Patent
AstraZeneca has fended off another challenge to a patent on its $3.5 billion diabetes drugs Onglyza and Kombiglyze, with the Patent Trial and Appeal Board finding Mylan Pharmaceuticals and other drugmakers...To view the full article, register now.
Already a subscriber? Click here to view full article